GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianda Pharmaceuticals Ltd (HKSE:00455) » Definitions » Earnings per Share (Diluted)

Tianda Pharmaceuticals (HKSE:00455) Earnings per Share (Diluted) : HK$-0.01 (TTM As of Dec. 2023)


View and export this data going back to 1992. Start your Free Trial

What is Tianda Pharmaceuticals Earnings per Share (Diluted)?

Tianda Pharmaceuticals's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was HK$-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.01.

Tianda Pharmaceuticals's EPS (Basic) for the six months ended in Dec. 2023 was HK$-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.01.

Tianda Pharmaceuticals's EPS without NRI for the six months ended in Dec. 2023 was HK$-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.01.

During the past 13 years, Tianda Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 97.20% per year. The lowest was -486.70% per year. And the median was -33.10% per year.


Tianda Pharmaceuticals Earnings per Share (Diluted) Historical Data

The historical data trend for Tianda Pharmaceuticals's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianda Pharmaceuticals Earnings per Share (Diluted) Chart

Tianda Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -0.01 -0.01 -0.01

Tianda Pharmaceuticals Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Jun23 Dec23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 - -0.01 - -0.01

Competitive Comparison of Tianda Pharmaceuticals's Earnings per Share (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Tianda Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tianda Pharmaceuticals's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tianda Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Tianda Pharmaceuticals's PE Ratio falls into.



Tianda Pharmaceuticals Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Tianda Pharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-24.155-0)/2150.042
=-0.01

Tianda Pharmaceuticals's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-20.028-0)/2150.042
=-0.01

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Tianda Pharmaceuticals  (HKSE:00455) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Tianda Pharmaceuticals Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Tianda Pharmaceuticals's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Tianda Pharmaceuticals (HKSE:00455) Business Description

Traded in Other Exchanges
N/A
Address
CITIC Tower, No. 1 Tim Mei Avenue, Suites 2405-2410, 24th Floor, Central, Hong Kong, HKG
Tianda Pharmaceuticals Ltd is engaged in R&D, manufactures and sales of pharmaceutical, biotechnology and healthcare products. The group also engages in R&D of Chinese medicine and manufacture and sales of Chinese medicine products, and the provision of Chinese medical services. Its operating segments include Chinese medicine business; Medical and healthcare services; and Pharmaceuticals and medical technologies business. The company derives majority of the revenue from Pharmaceuticals and medical technologies business.
Executives
Tianda Group Limited 2101 Beneficial owner
Fang Wen Quan 2201 Interest of corporation controlled by you

Tianda Pharmaceuticals (HKSE:00455) Headlines

No Headlines